Compare Abbott Laboratories (ABT) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vertiv Holdings Co — how do they compare? Abbott Laboratories trades at $95.66 (market cap $166.94B), while Vertiv Holdings Co trades at $312.84 (market cap $117.38B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | VRT | |
|---|---|---|
Market Cap | $166.94B | $117.38B |
Sector | Health | Technology |
52-Week High | $136.62 | $376.23 |
52-Week Low | $82.57 | $120.72 |
Enterprise Value | $193.69B | $118.14B |
Dividend Yield | 2.63% | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Vertiv Holdings (VRT) trades at $318.47, up 5.97% with strong bullish momentum. The stock shows robust fundamentals with Q1 2026 EPS beating estimates at $1.17 versus $1.00 expected, continuing a pattern of earnings outperformance. Technical indicators signal bullish momentum with the current price near pivot point resistance at $319. The company benefits from AI infrastructure demand, supported by recent manufacturing expansion in Malaysia and strategic acquisitions enhancing its data center portfolio.
Outlook remains positive with 94.7% analyst buy ratings and a $395.23 consensus price target implying 24% upside. Key risks include premium valuation multiples (P/E 80.02) and execution challenges in scaling operations. The AI infrastructure boom presents significant growth opportunity, though investors should monitor competitive pressures and macroeconomic conditions affecting data center spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
